Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Novartis posts Cosentyx nail psoriasis and imatinib results; Piqray label updatedOct 30Weekly roundup, 8 itemsalpelisibeverolimusUpdated
Novartis updates Phase IIIb ribociclib adjuvant breast cancer trial; four prior items holdOct 23Weekly roundup, 5 itemsarumakimigNovartisUpdated
Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studiesOct 16Weekly roundup, 7 itemsianalumabNovartis
FDA approves supplement 13 for Cosentyx, Novartis's secukinumabOct 15Regulatory decisionNovartissecukinumab
Novartis: Myfortic label update approved; M.D. Anderson posts endometrial trial resultsJul 31Weekly roundup, 6 itemsabelacimabDDY391
Novartis posts BioItaLEE and China ribociclib results; registers three new studiesJul 10Weekly roundup, 5 itemsalpelisibinclisiran